Supernus Pharmaceuticals, Inc.

Day range

$39.58 – $40.72

Open

$40.72

Prev close

$40.70

Volume

581.22K

Market cap

$2.37B

Shares out

58.22M

P/E

—

P/S

2.85

P/B

2.30

P/FCF

126.14

ROE

-10.7%

ROA

-7.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionOct 22, 2026

  The Company issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson's disease. The seven-year market exclusivity for ONAPGO began on February 3, 2025, the date of FDA approval.

• Special meeting resultsOct 15, 2026

  On October 15, 2026 Supernus Pharmaceuticals, Inc. (the "Company") held a special meeting of its stockholders (the "Special Meeting"). Proposal 1, adoption of the Merger Agreement, was approved with 48,249,532 votes for, 235,601 against, and 67,004 abstentions.

• Merger agreementAug 3, 2026

  On August 1, 2026, Supernus Pharmaceuticals, Inc. entered into a Merger Agreement by and among the Company, Indivior Pharmaceuticals Inc., and Artemis Merger Sub, Inc. Pursuant to the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Indivior. Each share of common stock of the Company will be converted into the right to receive 1.5401 shares of common stock of Indivior.

• Merger agreementAug 3, 2026

  As previously announced, Supernus and Invidior Pharmaceuticals, Inc. ("Invidior") have entered into a definitive agreement to combine in an all-stock merger of equals (the "Merger").

• Investor presentationAug 3, 2026

  on August 3, 2026, Supernus Pharmaceuticals, Inc. (the "Company") and Indivior Pharmaceuticals Inc. ("Indivior") are hosting a conference call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger of the Company and Indivior. The Company intends to display the slides filed as Exhibit 99.1 hereto during the presentation.

Days to cover

7.4

Short interest

4.99M

Avg volume

676K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
  positiveGlobeNewswire Inc.· Oct 21, 2026
• Why Supernus Pharmaceuticals Stock Topped the Market Today
  positiveThe Motley Fool· Aug 3, 2026
• Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
  negativeGlobeNewswire Inc.· Aug 3, 2026
• Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
  positiveGlobeNewswire Inc.· May 6, 2026
• Supernus Pharmaceuticals to Participate in March Investor Conferences
  neutralGlobeNewswire Inc.· Feb 23, 2026